Endpoints News reviews 77 E11 startups; highlights include Candid's $2B UCB buyout, Isomorphic Labs' $2.1B raise, Orca Bio's FDA approval, and Areteia's closure.
September 10, 2026 10:30 AM EDT
How past Endpoints 11 winners fared as the biotech industry rebounded
Kyle LaHucik
Biotech Correspondent
We’ll be unveiling this year’s Endpoints 11 in Boston on the night of Sept. 24. Join us.
Endpoints opens nominations for its 2026 Endpoints 11 awards; submit standout private biotech startups by July 14 ahead of the…
Welcome back to Endpoints Weekly! Don’t miss Ryan Cross’ deep dive into the paranoia caused by competition with China. Ryan…
Welcome back to Endpoints Weekly! This week, we opened nominations for our eighth annual Women in Biopharma report. We’re looking…
Sarepta delays Elevidys non-ambulatory study to Q1 2027; Emergent cuts 90 roles; Context axes CT-95; argenx sole bidder for…
Welcome back to another edition of Endpoints Weekly! We hope you all have been staying safe indoors as the Canadian wildfires…
Biotech megarounds rebounded in the first half of 2026, with 40 companies raising $100M+, up from 33 in the same period last year.
